In part 2 of our interview with Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine, we discuss the challenge inherent ...
A breakthrough discovery in enzyme science could revolutionize the treatment of autoimmune disorders and other diseases tied ...
KFDA approves Argenxs Vibgart for severe myasthenia gravis treatment KFDA greenlights innovative therapy for muscle weakness caused by autoimmune disease ...
UCB, a global biopharmaceutical company, today announced the CHMP (Committee for Medicinal Products for Human Use) has issued a positive opinion for the self-administration of RYSTIGGO® ...
TIGIT (T-cell immunoreceptor with immunoglobulin and ITIM domains ... Domvanalimab is Fc-silenced, meaning it does not bind to the Fc receptors found on immune cells, thereby leaving those ...
With an Fc-engineered design, CLYM116 targets APRIL signalling, a key factor in B-cell-mediated diseases. The antibody's mechanism of action includes blocking APRIL's binding to its receptors and ...
evaluate Fc-dependent functional antibodies ... underlie the differences observed in Fcγ-receptor-binding (types I, IIa, and IIIa/b), IgG, IgM, and IgA production, and complement-fixing antibodies.
Detailed price information for Iteos Therapeutics Inc (ITOS-Q) from The Globe and Mail including charting and trades.
With an Fc-engineered design, CLYM116 targets APRIL signalling, a key factor in B-cell-mediated diseases. The antibody’s mechanism of action includes blocking APRIL’s binding to its receptors and ...
CeRMS (Center for Research and Medical Studies), A.O. Città della Salute e della Scienza di Torino, Torino, Italy. Department of Orthopaedics, A.O. Città della Salute e della Scienza di Torino, Torino ...